yahoo_financeOriginal article
Corbus CRB-913 Delivers 5% Weight Loss in Phase 1b Obesity Study
positiveCRB-913Positive
AI Analysis
Summary
Corbus announced that CRB-913 achieved a 5% weight loss result in a Phase 1b obesity study. This early-stage clinical data demonstrates potential efficacy for the obesity indication.
Clinical Trial Data
Phase
1b
Primary Endpoint
Met
Outcome Details
5% weight loss achieved
Importance:5/10
Sentiment:
0.70
obesityPhase 1bweight lossclinical data
Related Companies
Read the original article
Published by yahoo_finance on September 15, 2026 8:02 AM